ERBB2 and breast carcinoma: The introduction of HER2-targetd therapies, including the monoclonal antibodies anti-HER2 trastuzumab and pertuzumumab and the HER2 tyrosine kinase inhibitor lapatinib, has revolutionized the therapy and substantially improved the outcomes of patients with HER2-positive breast cancers.